June 7, 2018

Hope Pharmaceuticals Files Supplemental New Drug Application to the Food and Drug Administration for Sodium Thiosulfate Injection

Hope Pharmaceuticals Files Supplemental New Drug Application to the Food and Drug Administration for Sodium Thiosulfate Injection

 

For Immediate Release:           June 7, 2018

Media Inquiries:                      Craig Sherman, M.D.

(480) 607-1970 or questions@hopepharm.com

 

Scottsdale, Arizona June 7, 2018 – Hope Pharmaceuticals today announced that the company filed a Supplemental New Drug Application to the United States Food and Drug Administration (FDA) for the use of Sodium Thiosulfate Injection to prevent a potential complication associated with the administration of a chemotherapeutic agent.

Hope Pharmaceuticals’ Sodium Thiosulfate Injection has already been approved by the FDA as an antidote for acute cyanide poisoning that is judged to be life-threatening and is currently distributed in the United States in individually-packaged 50 mL vials.

Additional information about Sodium Thiosulfate Injection is available online at www.thiosulfate.info.

Hope Pharmaceuticals is a privately owned company located in Scottsdale, Arizona.

####